INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
77.71
+1.34 (+1.75%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close76.37
Open76.30
Bid71.00 x 800
Ask77.90 x 1000
Day's Range75.46 - 77.79
52 Week Range57.00 - 88.83
Volume1,250,414
Avg. Volume1,283,293
Market Cap16.664B
Beta (3Y Monthly)1.01
PE Ratio (TTM)66.88
EPS (TTM)1.16
Earnings DateJul 29, 2019 - Aug 2, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est88.06
Trade prices are not sourced from all markets
  • Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend — traders to sell the rally
    Yahoo Finance Video9 days ago

    Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend — traders to sell the rally

    Joining Yahoo Finance's Jen Rogers and Myles Udland is Jared Blikre to break down the week's market action in the S&P 500, its 11 sectors (where tech is leading the year again), as well as the weekly winners in the Nasdaq 100 — all with the help of our new YFi Interactive touch screen.

  • Markityesterday

    See what the IHS Markit Score report has to say about Incyte Corp.

    Incyte Corp NASDAQ/NGS:INCYView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for INCY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding INCY totaled $2.93 billion. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wireyesterday

    Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

    Incyte (INCY) today announces 24-week results from its randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients (18 to 75 years of age) with vitiligo. The study met its primary endpoint, demonstrating that significantly more patients treated with ruxolitinib cream for 24 weeks achieved a ≥50 percent improvement from baseline in the facial vitiligo area severity index (F-VASI50) score compared to patients treated with a vehicle control (non-medicated cream).

  • Here’s What Hedge Funds Think About Incyte Corporation (INCY)
    Insider Monkey2 days ago

    Here’s What Hedge Funds Think About Incyte Corporation (INCY)

    Is Incyte Corporation (NASDAQ:INCY) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]

  • Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
    Zacks3 days ago

    Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I

    Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.

  • Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock
    Zacks3 days ago

    Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock

    Here are five reasons why investors may consider betting on Merck (MRK) stock

  • Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study
    Zacks3 days ago

    Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study

    Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.

  • Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer
    Zacks4 days ago

    Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer

    Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.

  • American City Business Journals9 days ago

    9 interesting things heard during BIO 2019 (Photos)

    Philadelphia’s fourth turn hosting the Biotechnology Innovation Organization’s annual international conference concluded Thursday. The BIO 2019 event featured a variety of panel discussions, keynote interviews, fireside chats and company presentations, covering a myriad of topics in the life sciences industry.

  • Incyte Begins Phase III Study for Treatment of Duct Cancer
    Zacks10 days ago

    Incyte Begins Phase III Study for Treatment of Duct Cancer

    Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.

  • Celgene (CELG) Presents Data on Pipeline Candidates at ASCO
    Zacks11 days ago

    Celgene (CELG) Presents Data on Pipeline Candidates at ASCO

    Celgene (CELG) presents data on myelofibrosis candidate from a phase II study and an oncology candidate at ASCO.

  • Looking For Growth? Take A Look At These Biotechnology Stocks
    Investor's Business Daily12 days ago

    Looking For Growth? Take A Look At These Biotechnology Stocks

    The best biotech companies to invest in tend to have a commonality: A strong streak of earnings growth.

  • Business Wire12 days ago

    Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Pemigatinib as a First-Line Therapy for Cholangiocarcinoma

    Incyte (INCY) today announced that the first patient has been treated in FIGHT-302, an open-label Phase 3 study evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, compared to gemcitabine with cisplatin chemotherapy, the current standard of care, as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) and activating FGFR2 rearrangements. “We are pleased to initiate FIGHT-302 – the first Phase 3 study of pemigatinib – which we hope will add to the growing body of evidence demonstrating its potential as a safe and effective treatment for patients with cholangiocarcinoma with known FGFR2 rearrangements, a rare and potentially life-threatening form of cancer,” said Steven Stein, M.D., Chief Medical Officer, Incyte.

  • Novartis (NVS) Announces Various Data Presentations at ASCO
    Zacks13 days ago

    Novartis (NVS) Announces Various Data Presentations at ASCO

    Novartis (NVS) announces a number of data presentations at the ASCO 2019 annual meeting.

  • Business Wire13 days ago

    New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results in Patients with Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation Treated with Capmatinib

    WILMINGTON, Del.-- -- Primary efficacy analysis demonstrated promising efficacy for capmatinib irrespective of the prior line of therapy in 97 patients: overall response rate was 68 percent and 41 percent and median duration of response was 11.14 months and 9.72 months, respectively, across treatment-naive and previously-treated patients with locally advanced or metastatic non-small cell lung cancer ...

  • Benzinga15 days ago

    The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

    Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. The unfolding ...

  • Mesoblast Starts Rolling BLA Submission for Remestemcel-L
    Zacks17 days ago

    Mesoblast Starts Rolling BLA Submission for Remestemcel-L

    Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.

  • Why Is Incyte (INCY) Down 1.7% Since Last Earnings Report?
    Zacks17 days ago

    Why Is Incyte (INCY) Down 1.7% Since Last Earnings Report?

    Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion
    Zacks18 days ago

    Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • The Zacks Analyst Blog Highlights: Medtronic, TJX, Deere, Incyte and Netapp
    Zacks19 days ago

    The Zacks Analyst Blog Highlights: Medtronic, TJX, Deere, Incyte and Netapp

    The Zacks Analyst Blog Highlights: Medtronic, TJX, Deere, Incyte and Netapp

  • FDA approves Incyte's Jakafi as graft-versus-host disease therapy
    American City Business Journals19 days ago

    FDA approves Incyte's Jakafi as graft-versus-host disease therapy

    The Food and Drug Administration on Friday approved Incyte Corp.’s application for a wide approval of its flagship product Jakafi. The FDA approved the use of the medication to treat patients age 12 and older with acute graft-versus-host disease (GVHD) who do not respond to corticosteroids. "For the first time, patients with steroid-refractory acute GVHD, and the physicians that treat them, have an FDA-approved treatment for this serious disease,” said Hervé Hoppenot, CEO of Incyte.

  • GlobeNewswire19 days ago

    BriaCell’s Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that BriaCell’s clinical findings were published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings, a supplement to the Journal of Clinical Oncology. ASCO’s Annual Meeting, taking place May 31-June 4, 2019 at the McCormick Place Convention Center in Chicago, IL, represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology.